IDEXX Laboratories (NASDAQ:IDXX) Issues Earnings Results

IDEXX Laboratories (NASDAQ:IDXX) released its quarterly earnings results on Tuesday. The company reported $3.47 EPS for the quarter, beating analysts’ consensus estimates of $3.41 by $0.06, Zacks reports. IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The firm had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.12 billion. During the same period in the previous year, the business earned $2.91 earnings per share. The company’s revenue for the quarter was up 14.3% compared to the same quarter last year. IDEXX Laboratories updated its FY 2026 guidance to 14.450-14.900 EPS.

Here are the key takeaways from IDEXX Laboratories’ conference call:

• Raised full‑year guidance — revenue now $4.675B–$4.76B and EPS $14.45–$14.90, with organic revenue growth guidance of 7.7%–9.7% and CAG Diagnostics recurring growth of 8.7%–10.7%, reflecting a roughly $42M midpoint improvement from Q1 execution.
• Strong Q1 operating performance — revenue +14% reported (+11% organic), CAG Diagnostics recurring revenue +11%, 1,100 InViewDX placements and 28% organic instrument revenue growth, VetLab consumables +15%, and a 100 bp comparable operating margin gain driving 15% comparable EPS growth.
• Demand headwinds in visits — U.S. same‑store clinical visits declined ~1% in Q1 (wellness visits -3%) and the company is guiding to ~-1.5% U.S. clinical visits for the year, which could constrain future volume growth if trends persist.
• One‑time and FX effects — Q1 included a $5M loss on an equity investment (~$0.05 EPS headwind) and a prior litigation expense (~30 bp margin impact), while FX added about $0.14 to EPS; balance sheet remains strong (0.5x net leverage) after $361M of share repurchases.

IDEXX Laboratories Stock Performance

IDXX traded up $13.52 during trading on Wednesday, hitting $576.49. 164,531 shares of the company traded hands, compared to its average volume of 522,834. The firm has a market cap of $45.79 billion, a P/E ratio of 44.20, a price-to-earnings-growth ratio of 3.42 and a beta of 1.58. The stock’s fifty day moving average is $588.09 and its 200 day moving average is $650.80. The company has a quick ratio of 0.90, a current ratio of 1.23 and a debt-to-equity ratio of 0.23. IDEXX Laboratories has a one year low of $471.74 and a one year high of $769.98.

Key Stories Impacting IDEXX Laboratories

Here are the key news stories impacting IDEXX Laboratories this week:

• Positive Sentiment: Q1 results beat expectations: IDEXX reported $3.47 EPS vs. consensus ~$3.41 and revenue of $1.141B (up ~14% y/y). Results showed organic growth in Companion Animal Group and margin improvement, supporting near‑term earnings momentum. IDEXX Laboratories Announces First Quarter Results
• Positive Sentiment: Company raised FY‑2026 EPS guidance to $14.450–$14.900 (consensus ~14.52), signaling management confidence in diagnostics growth and innovation — a bullish catalyst for forward earnings expectations. IDEXX Laboratories Lifts Guidance on Robust Q1
• Neutral Sentiment: Earnings-call materials and transcript provide color on drivers (diagnostics cadence, CAG strength, product cadence) for analysts and investors to model forward growth; see the slides and full call transcript for management commentary. IDEXX Laboratories, Inc. 2026 Q1 – Results – Earnings Call Presentation IDEXX Laboratories, Inc. (IDXX) Q1 2026 Earnings Call Transcript
• Neutral Sentiment: Several analyst/news writeups highlight the beat, margin expansion and guidance lift — useful for gauging consensus revisions and sentiment changes that may drive near‑term analyst actions. IDEXX Stock Up on Q1 Earnings & Revenue Beat, Margins Rise, ’26 View Up
• Negative Sentiment: Valuation concern: commentary and articles question whether IDXX’s recent ~18% one‑year rally leaves less upside, prompting some investors to reassess risk/reward despite the beat and guidance. That valuation debate may pressure the stock even after strong fundamentals. Is It Too Late To Consider IDEXX Laboratories (IDXX) After Its 18.5% One-Year Rally?

Insider Activity

In other IDEXX Laboratories news, EVP George Fennell sold 11,345 shares of the stock in a transaction dated Tuesday, February 10th. The shares were sold at an average price of $646.72, for a total transaction of $7,337,038.40. Following the completion of the transaction, the executive vice president owned 9,823 shares in the company, valued at $6,352,730.56. This trade represents a 53.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Jonathan Jay Mazelsky sold 23,326 shares of the firm’s stock in a transaction that occurred on Thursday, February 26th. The shares were sold at an average price of $657.55, for a total transaction of $15,338,011.30. Following the completion of the transaction, the chief executive officer owned 83,606 shares of the company’s stock, valued at $54,975,125.30. This trade represents a 21.81% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 45,957 shares of company stock valued at $29,862,109. 0.79% of the stock is currently owned by corporate insiders.

Institutional Trading of IDEXX Laboratories

Hedge funds have recently modified their holdings of the business. Wellington Management Group LLP boosted its stake in IDEXX Laboratories by 318.1% in the 4th quarter. Wellington Management Group LLP now owns 779,214 shares of the company’s stock worth $527,162,000 after purchasing an additional 592,834 shares in the last quarter. Price T Rowe Associates Inc. MD grew its stake in shares of IDEXX Laboratories by 37.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 952,223 shares of the company’s stock valued at $644,208,000 after acquiring an additional 258,015 shares during the period. Zurich Insurance Group Ltd FI bought a new position in shares of IDEXX Laboratories during the 3rd quarter valued at approximately $143,730,000. Invesco Ltd. grew its stake in shares of IDEXX Laboratories by 13.8% during the 4th quarter. Invesco Ltd. now owns 1,502,218 shares of the company’s stock valued at $1,016,296,000 after acquiring an additional 181,955 shares during the period. Finally, State Street Corp grew its stake in shares of IDEXX Laboratories by 4.0% during the 4th quarter. State Street Corp now owns 3,656,626 shares of the company’s stock valued at $2,473,817,000 after acquiring an additional 138,956 shares during the period. Institutional investors own 87.84% of the company’s stock.

Analyst Upgrades and Downgrades

IDXX has been the subject of several research reports. Piper Sandler lowered their price objective on shares of IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating for the company in a research report on Monday, February 9th. Citigroup started coverage on shares of IDEXX Laboratories in a research report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price target on the stock. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of IDEXX Laboratories in a research report on Monday, April 27th. UBS Group decreased their target price on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a report on Tuesday, April 28th. Finally, BTIG Research decreased their target price on shares of IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating on the stock in a report on Tuesday, February 3rd. Seven equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $751.00.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.